Drawing for BELEMSI

USPTO serial 79332046

BELEMSI

Reviewed by CopyMark Law Group

Reg. 7209332Status 700Registered
Filing date
Status date
Registration date
Nov 7, 2023
Examiner
WHITE, TRAVIS WILLIAM
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with BELEMSI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 11, 2023CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Nov 7, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Nov 7, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 6, 2023OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Nov 1, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 1, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Nov 1, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 1, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 1, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Nov 1, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 22, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 22, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 2, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 2, 2023OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Aug 2, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 31, 2023OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jul 18, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 14, 2023PC.DPETITION TO DIRECTOR DISMISSED—
Jul 14, 2023MREINOTICE OF REINSTATEMENT E-MAILED—
Jul 12, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 12, 2023OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jul 11, 2023DOCKASSIGNED TO EXAMINER—
Jul 11, 2023REINREINSTATED—
May 25, 2023APETASSIGNED TO PETITION STAFF—
Feb 3, 2023TPDRTEAS PETITION TO DIRECTOR RECEIVED—
Feb 21, 2022DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
Feb 20, 2022DETHDEATH OF INTERNATIONAL REGISTRATION—
Feb 15, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 9, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 2, 2022LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Jan 27, 2022SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance